FDA approves lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma after ≥2 prior systemic therapies, with ORR 84.4% and CRR 55.8% in TRANSCEND FL-MZL Cohort - Vera Health News